IGFBP3

IGFBP3 Full Name

insulin-like growth factor binding protein 3

IGFBP3 Introduction

IGFBP3 (Insulin-like Growth Factor Binding Protein 3) is located on chromosome 7q22.2, spanning approximately 8.9 kb and containing 5-6 exons that encode multiple transcript variants through alternative splicing. The gene produces a 264-291 amino acid precursor protein that undergoes proteolytic processing to generate the mature, secreted glycoprotein. Structurally, IGFBP3 contains three conserved domains of approximately 40-50 amino acids each: an N-terminal IGFBP domain with twelve conserved cysteines forming disulfide bonds essential for IGF binding, a central linker domain susceptible to proteolysis, and a C-terminal thyroglobulin type-1 domain that mediates interactions with acid-labile subunit (ALS) and other binding partners. The protein also features a nuclear localization sequence, heparin-binding domain, and multiple phosphorylation sites that modulate its functional diversity.

Figure 1. IGFBP-3 binds HA and blocks its interaction with CD44 resulting in increased AChE expression and activity in a p53-dependent manner leading to apoptosis and decreased cell survival.(Price D, 2020)

IGF-Dependent and IGF-Independent Functional Mechanisms
IGFBP3 exhibits dual functionality through both IGF-dependent and IGF-independent mechanisms. In its classical IGF-dependent role, IGFBP3 binds insulin-like growth factors I and II with high affinity, forming a ternary complex of approximately 140-150 kDa with IGFALS and either IGF-I or IGF-II, which prolongs the circulating half-life of IGFs and modulates their interaction with cell surface receptors. This sequestration limits IGF bioavailability and suppresses IGF-mediated cell growth and survival signaling. In its IGF-independent capacity, IGFBP3 directly regulates cellular processes including apoptosis, cell cycle progression, and autophagy through interaction with specific cell surface receptors such as TMEM219/IGFBP-3R. The protein induces apoptosis through p53- and IGF-independent pathways, as demonstrated in prostate cancer cells where recombinant IGFBP-3 treatment resulted in dose-dependent apoptosis mediated by membrane-associated receptor proteins. IGFBP3 also inhibits NF-κB transcriptional activity, contributing to its anti-inflammatory effects.

Role in Cancer Biology and Therapeutic Implications
IGFBP3 exhibits complex, context-dependent roles in tumor development and progression, functioning as both tumor suppressor and oncogene depending on cellular context and tumor microenvironment. Aberrant IGFBP3 expression is documented in numerous malignancies including breast cancer, hepatocellular carcinoma, lung cancer, prostate cancer, and glioma, where serum and tissue levels provide auxiliary information for assessing tumor malignancy and patient prognosis. In glioma, IGFBP3 serves as an independent prognostic biomarker, with functional studies demonstrating that IGFBP3 knockdown suppresses invasive and migratory capacities of U87MG cells through inhibition of the PI3K/Akt/mTOR signaling pathway, while also affecting the tumor immune microenvironment. The protein exhibits dichotomous behavior: in certain contexts it inhibits cancer cell growth through IGF sequestration and pro-apoptotic effects, while in other pathological conditions it may contribute to cancer cell survival. This dual functionality positions IGFBP3 as a potential therapeutic target, with applications as a standalone therapeutic agent, pharmacological target in combination with chemotherapy or radiotherapy, or as a molecular scaffold for novel drug design.

Alternate Names for IGFBP3

IGFBP3; insulin-like growth factor binding protein 3; IBP3; BP-53; insulin-like growth factor-binding protein 3; IBP-3; IGFBP-3; binding protein 29; binding protein 53; IGF-binding protein 3; growth hormone-dependent binding protein; acid stable subunit of the 140 K IGF complex;